Literature DB >> 20406819

Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms.

Vindhya Nawaratne1, Katie Leach, Christian C Felder, Patrick M Sexton, Arthur Christopoulos.   

Abstract

The recently identified small molecule, 3-amino-5-chloro-6-methoxy-4-methylthieno[2,3-b]pyridine-2-carboxylic acid cyclopropylamide (LY2033298), is the first selective allosteric modulator of the muscarinic acetylcholine receptors (mAChRs) that mediates both receptor activation and positive modulation of the endogenous agonist, acetylcholine (ACh), via the same allosteric site on the M(4) mAChR. We thus utilized this novel chemical tool, as well as ACh, the bitopic (orthosteric/allosteric) agonist, McN-A-343, and the clinically efficacious M(1)/M(4) mAChR-preferring agonist, xanomeline, in conjunction with site-directed mutagenesis of four different regions of the M(4) mAChR (extracellular loops 1, 2, and 3, and transmembrane domain 7), to identify regions that govern ligand-specific modes of binding, signaling, and allosteric modulation. In the first extracellular loop (E1), we identified Ile(93) and Lys(95) as key residues that specifically govern the signaling efficacy of LY2033298 and its binding cooperativity with ACh, whereas Phe(186) in the E2 loop was identified as a key contributor to the binding affinity of the modulator for the allosteric site, and Asp(432) in the E3 loop appears to be involved in the functional (activation) cooperativity between the modulator and the endogenous agonist. In contrast, the highly conserved transmembrane domain 7 residues, Tyr(439) and Tyr(443), were identified as contributing to a key activation switch utilized by all classes of agonists. These results provide new insights into the existence of multiple activation switches in G protein-coupled receptors (GPCRs), some of which can be selectively exploited by allosteric agonists, whereas others represent global activation mechanisms for all classes of ligand.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406819      PMCID: PMC2885178          DOI: 10.1074/jbc.M110.125096

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Discovery of an ectopic activation site on the M(1) muscarinic receptor.

Authors:  Tracy A Spalding; Carol Trotter; Niels Skjaerbaek; Terri L Messier; Erika A Currier; Ethan S Burstein; Donghui Li; Uli Hacksell; Mark R Brann
Journal:  Mol Pharmacol       Date:  2002-06       Impact factor: 4.436

Review 2.  Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox.

Authors:  Christopher J Langmead; Arthur Christopoulos
Journal:  Trends Pharmacol Sci       Date:  2006-08-04       Impact factor: 14.819

3.  Operational models of pharmacological agonism.

Authors:  J W Black; P Leff
Journal:  Proc R Soc Lond B Biol Sci       Date:  1983-12-22

4.  Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors.

Authors:  A L Gnagey; M Seidenberg; J Ellis
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide.

Authors:  Xi-Ping Huang; Stefanie Prilla; Klaus Mohr; John Ellis
Journal:  Mol Pharmacol       Date:  2005-06-03       Impact factor: 4.436

7.  Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.

Authors:  Lei Ma; Matthew A Seager; Matthew Seager; Marion Wittmann; Marlene Jacobson; Denise Bickel; Maryann Burno; Keith Jones; Valerie Kuzmick Graufelds; Guangping Xu; Michelle Pearson; Alexander McCampbell; Renee Gaspar; Paul Shughrue; Andrew Danziger; Christopher Regan; Rose Flick; Danette Pascarella; Susan Garson; Scott Doran; Constantine Kreatsoulas; Lone Veng; Craig W Lindsley; William Shipe; Scott Kuduk; Cyrille Sur; Gene Kinney; Guy R Seabrook; William J Ray
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

8.  Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Authors:  Anantha Shekhar; William Z Potter; Jeffrey Lightfoot; John Lienemann; Sanjay Dubé; Craig Mallinckrodt; Frank P Bymaster; David L McKinzie; Christian C Felder
Journal:  Am J Psychiatry       Date:  2008-07-01       Impact factor: 18.112

Review 9.  Conformational changes involved in G-protein-coupled-receptor activation.

Authors:  Jürgen Wess; Sung-Jun Han; Soo-Kyung Kim; Kenneth A Jacobson; Jian Hua Li
Journal:  Trends Pharmacol Sci       Date:  2008-10-04       Impact factor: 14.819

10.  Allosteric modulation of muscarinic acetylcholine receptors.

Authors:  Karen J Gregory; Patrick M Sexton; Arthur Christopoulos
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

View more
  23 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.

Authors:  S Suratman; K Leach; Pm Sexton; Cc Felder; Re Loiacono; A Christopoulos
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

4.  Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator.

Authors:  Nicola J Smith; Richard J Ward; Leigh A Stoddart; Brian D Hudson; Evi Kostenis; Trond Ulven; Joanne C Morris; Christian Tränkle; Irina G Tikhonova; David R Adams; Graeme Milligan
Journal:  Mol Pharmacol       Date:  2011-04-15       Impact factor: 4.436

Review 5.  Emerging paradigms in GPCR allostery: implications for drug discovery.

Authors:  Denise Wootten; Arthur Christopoulos; Patrick M Sexton
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

Review 6.  Lifting the lid on GPCRs: the role of extracellular loops.

Authors:  M Wheatley; D Wootten; M T Conner; J Simms; R Kendrick; R T Logan; D R Poyner; J Barwell
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

7.  Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor.

Authors:  Alaa Abdul-Ridha; Laura López; Peter Keov; David M Thal; Shailesh N Mistry; Patrick M Sexton; J Robert Lane; Meritxell Canals; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

8.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  Species differences and mechanism of action of A3 adenosine receptor allosteric modulators.

Authors:  Lili Du; Zhan-Guo Gao; Silvia Paoletta; Tina C Wan; Elizabeth T Gizewski; Samantha Barbour; Jacobus P D van Veldhoven; Adriaan P IJzerman; Kenneth A Jacobson; John A Auchampach
Journal:  Purinergic Signal       Date:  2017-11-23       Impact factor: 3.765

10.  Crystal structures of the M1 and M4 muscarinic acetylcholine receptors.

Authors:  David M Thal; Bingfa Sun; Dan Feng; Vindhya Nawaratne; Katie Leach; Christian C Felder; Mark G Bures; David A Evans; William I Weis; Priti Bachhawat; Tong Sun Kobilka; Patrick M Sexton; Brian K Kobilka; Arthur Christopoulos
Journal:  Nature       Date:  2016-03-09       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.